RxDoctor Payments Data

Andrew Rosenstein, MD

Gastroenterology · Baltimore, MDNPI 1275615486

Payments from drug & device makers

$13,812in general payments, 2019–2025

Across 336 payments — averaging $41.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$553
  • Braintree Laboratories, Inc.$497
  • Bristol Myers Squibb$462
  • Amgen$416
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$7,12552%
  • Food & beverage$6,31046%
  • Education$470%
  • Gifts$3292%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,812 in reported general payments places this provider in the 80th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$215,265
Medicare patients
922
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase48$145,763
XifaxanRifaximin31$99,651
Mesalamine45$30,963
LinzessLinaclotide14$17,802
Dexlansoprazole DrDexlansoprazole30$10,535
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag90$10,505
Mesalamine ErMesalamine33$9,915
NexiumEsomeprazole Magnesium11$9,851
Budesonide DrBudesonide73$7,811
ClenpiqSod Picosulf/Mag Ox/Citric Ac42$7,180
Esomeprazole Magnesium80$6,956
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates60$3,743
Pantoprazole Sodium211$3,666
Balsalazide Disodium23$3,277
Budesonide EcBudesonide25$3,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$8,880$163,56562 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$195$99,65131 claims
Braintree Laboratories, Inc.Suflave, Sutab$497$13,144107 claims
Ferring Pharmaceuticals Inc.Clenpiq$39$7,18042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →